Market Cap$13.07B
P/E—
PEG Ratio36.68
Div yield3.22%
Beta0.66
BAX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)33.81%
Price vs S&P 500 (4W)11.57%
PEG Ratio36.68
VGM Score57.52
Indicated Dividend Yield (Annual)3.22%
BAX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.37 | $0.56 | +52.53%(+$0.19) | |
| Q1 2026 | $0.31 | $0.36 | +15.93%(+$0.05) | |
| Q4 2025 | $0.54 | $0.44 | -17.80%(-$0.10) | |
| Q3 2025 | $0.60 | $0.69 | +15.40%(+$0.09) | |
| Q2 2025 | $0.61 | $0.59 | -3.28%(-$0.02) |
BAX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
2.67
2.71
3.25
3.25
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
About Baxter International Inc.
Baxter supplies medical devices and therapies to hospitals and care settings, including injectable products, IV systems, nutritional solutions, and surgical sealants. The company expanded its hospital equipment portfolio through its 2021 Hillrom acquisition and divested its kidney care business in early 2025.